Effect of Advanced Hybrid Closed Loop System, MiniMed 780G in Newly Diagnosed Children and Adolescents With Type 1 Diabetes on Glycemic Control and Patient Reported Outcomes Compared to Standard Insulin Therapy Historical Data (AHCL in New Onset T1D Children Study)

Inclusion Criteria:

1. Clinical diagnosis of type 1 diabetes (WHO criteria). Diagnosis of type 1 diabetesis based on international criteria and the investigator's judgment; C peptide leveland antibody determinations are not required.

2. Age range 7 to 17 years.

3. Literate in Greek or English.

4. Willing to wear study devices.

5. Willing to follow study-specific instructions.

6. Total daily insulin dose greater than 8.0 units over 1 week period

7. Willing and able (access to internet from home) to download information into theMedtronic CareLink software

8. Clinically eligible to start the AHCL system

Exclusion Criteria:

• Type 2 diabetes mellitus or MODY diabetes

• Any untreated comorbidities of type 1 diabetes

• Medication affecting metabolic control or interfering in the interpretation of HbA1c

• Pregnancy

• Untreated diabetes retinopathy, or other causes that in the investigator's opinion,precludes the individual from participating in the trial.

• Known or suspected allergy to insulin.

• Regular use of acetaminophen.

• Lack of reliable telephone facility for contact.

• Living alone.

• Severe visual or hearing impairment.

• Medically documented allergy to the adhesive of plasters or unable to tolerate tapeadhesive around sensor placement.

• Serious skin lesions at areas of the body used for insertion of the glucose sensor.

• Illicit drugs abuse.

• Alcohol abuse.

• Sickle cell disease, haemoglobinopathy, receiving red blood cell transfusion orerythropoietin within 3 months prior to time of enrollment.

• Eating disorder including anorexia/bulimia.

• Milk protein allergy.